- Home
- UGI vs PTGX Comparison
UGI vs PTGX Comparison
Compare UGI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UGI | PTGX |
|---|---|---|
| Founded | 1940 | 2006 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.3B |
| IPO Year | 1994 | 2016 |
Fundamental Metrics
Financial Performance| Metric | UGI | PTGX |
|---|---|---|
| Price | $36.60 | $136.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $44.00 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.6M | 495.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 147.20 | N/A |
| EPS | ★ 3.08 | 2.35 |
| Revenue | ★ $7,287,000,000.00 | N/A |
| Revenue This Year | $8.88 | $874.25 |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | ★ $11.89 | $59.02 |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $31.62 | $62.24 |
| 52 Week High | $41.34 | $160.81 |
Technical Indicators
Market Signals| Indicator | UGI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 40.35 |
| Support Level | $36.75 | $130.63 |
| Resistance Level | $37.58 | $142.20 |
| Average True Range (ATR) | 0.59 | 4.74 |
| MACD | -0.24 | -0.99 |
| Stochastic Oscillator | 12.93 | 12.72 |
Price Performance
Historical ComparisonAbout UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.